RT Journal Article
SR Electronic
T1 Two-year follow up with patients treated with Zephyr valves over 10 years: Focus on safety
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P3713
VO 44
IS Suppl 58
A1 Hugo Oliveira
A1 Rafael Rambo
A1 Silvia Oliveira
A1 Amarilio Macedo-Neto
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P3713.abstract
AB Background: Endoscopic lung volume reduction (LVR) has become a therapeutic option for selected patients with advanced emphysema. Nevertheless, little is known about the long-term side effects of this treatment. Aim: To describe long-term follow-up of patients treated with Zephyr valves for emphysema and air leak. Methods: We retrospectively analyzed 84 treatments performed between June 4, 2002 and February 20, 2012 using Zephyr valves in 63 patients. Results: Four patients received valves for prolonged air leak and 59 for end-stage emphysema. In the emphysema group, 6 patients received a second treatment (contralateral) and 8 were treated using a staged approach. Of a total of 198 valves implanted, 26 were removed and 4 extruded in 16 patients. Three patients were retreated for dislodgment (1 twice) and 3 were retreated after valve removal due to infection. Treatment was completely reversed in 5 patients. Treatment was partially reversed due to pneumothorax in 2 patients. By February 20,2014, 43 patients had died (median survival 883 days). Sixteen are alive (median survival 1,286 days). All side effects associated with valve implantation were endoscopically managed. Figure 1 shows a 967 days endoscopic follow-up of a Zephyr valve.Conclusions: LVR with Zephyr valves is a safe procedure with reasonable performance at long follow-up. Selection criteria remain as the main challenge for applicability of this method.